{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:52:24Z","timestamp":1789674744315,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.metabol.2016.06.001","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T06:46:10Z","timestamp":1466059570000},"page":"1342-1349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges"],"prefix":"10.1016","volume":"65","author":[{"given":"Pingping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2014.74","article-title":"Therapeutic approaches to diabetic nephropathy\u2014beyond the RAS","volume":"10","author":"Fernandez-Fernandez","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"3 Suppl. 1","key":"10.1016\/j.metabol.2016.06.001_bb0010","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.metabol.2014.10.032","article-title":"Biomarkers of vascular complications in type 2 diabetes","volume":"64","author":"Tremblay","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2016.06.001_bb0015","doi-asserted-by":"crossref","first-page":"751513","DOI":"10.4061\/2011\/751513","article-title":"TRC120038, a novel dual AT(1)\/ET(a) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in Ob-ZSF1 rats","volume":"2011","author":"Mohanan","year":"2011","journal-title":"Int J Hypertens"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.HYP.0000240331.32352.0c","article-title":"Mechanisms of diabetic nephropathy: role of hypertension","volume":"48","author":"Giunti","year":"2006","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.metabol.2016.06.001_bb0025","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.metabol.2016.06.001_bb0030","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.metabol.2016.06.001_bb0045","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.1973.03220010068036","article-title":"Gynecomastia and impotence: complications of spironolactone therapy","volume":"223","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2016.06.001_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1389557054553811","article-title":"Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone","volume":"5","author":"Hu","year":"2005","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"10.1016\/j.metabol.2016.06.001_bb0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2009.244","article-title":"Heart failure: aldosterone antagonists are underused by clinicians","volume":"7","author":"Samuel","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0075","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"39","key":"10.1016\/j.metabol.2016.06.001_bb0080","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0085","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.metabol.2016.06.001_bb0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"issue":"1\u20133","key":"10.1016\/j.metabol.2016.06.001_bb0100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin\u2013angiotensin\u2013aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","article-title":"Effect of renin\u2013angiotensin\u2013aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker","volume":"31","author":"Furumatsu","year":"2008","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2011.06.100","article-title":"Aldosterone induces electrical remodeling independent of hypertension","volume":"164","author":"Dartsch","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/hr.2015.19","article-title":"The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy","volume":"38","author":"Sato","year":"2015","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0125","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1210\/en.2008-1018","article-title":"Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes","volume":"150","author":"Wada","year":"2009","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0130","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/HYPERTENSIONAHA.107.093955","article-title":"Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells","volume":"50","author":"Hitomi","year":"2007","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0135","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","article-title":"Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets","volume":"54","author":"Luther","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0140","doi-asserted-by":"crossref","first-page":"F559","DOI":"10.1152\/ajprenal.00320.2001","article-title":"New ideas about aldosterone signaling in epithelia","volume":"282","author":"Stockand","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J Endocrinol"},{"issue":"16","key":"10.1016\/j.metabol.2016.06.001_bb0150","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"issue":"39","key":"10.1016\/j.metabol.2016.06.001_bb0155","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"issue":"36","key":"10.1016\/j.metabol.2016.06.001_bb0160","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0165","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/14656566.2014.874415","article-title":"Comparative effect of canrenone or hydrochlorothiazide addition to valsartan\/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria","volume":"15","author":"Fogari","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.metabol.2016.06.001_bb0190","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0195","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0200","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"31","key":"10.1016\/j.metabol.2016.06.001_bb0205","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"Am J Nephrol"},{"issue":"9","key":"10.1016\/j.metabol.2016.06.001_bb0215","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ejhf.218","article-title":"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and\/or chronic kidney disease","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.metabol.2016.06.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.metabol.2016.06.001_bb0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jama.2015.15996","article-title":"Finerenone for albuminuria in patients with diabetic nephropathy","volume":"315","author":"Feng","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0235","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2016.06.001_bb0240","first-page":"S14","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0245","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5301\/JN.2011.6445","article-title":"Renal protection with angiotensin receptor blockers: where do we stand","volume":"24","author":"Schmieder","year":"2011","journal-title":"J Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0250","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.hjh.0000357904.71080.7d","article-title":"Effects of angiotensin II receptor blockers on diabetic nephropathy","volume":"27","author":"Kalaitzidis","year":"2009","journal-title":"J Hypertens Suppl"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2016.06.001_bb0255","first-page":"S5","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2016.06.001_bb0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.metabol.2016.06.001_bb0265","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"issue":"9","key":"10.1016\/j.metabol.2016.06.001_bb0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"11","key":"10.1016\/j.metabol.2016.06.001_bb0275","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin\u2013angiotensin\u2013aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0280","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin a nephropathy","volume":"11","author":"Horita","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0285","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin\u2013angiotensin\u2013aldosterone system alterations","volume":"116","author":"Te","year":"2015","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.metabol.2016.06.001_bb0290","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0295","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"12","key":"10.1016\/j.metabol.2016.06.001_bb0305","doi-asserted-by":"crossref","first-page":"F1026","DOI":"10.1152\/ajprenal.00220.2015","article-title":"Effect of mineralocorticoid treatment in mice with collecting duct-specific knockout of endothelin-1","volume":"309","author":"Lynch","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0310","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1476-5381.2012.02070.x","article-title":"Endothelin-1 and the kidney\u2014beyond BP","volume":"167","author":"Dhaun","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0315","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.2014020174","article-title":"Endothelin antagonists in diabetic nephropathy: back to basics","volume":"25","author":"Chandrashekar","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0320","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1476-5381.2012.01922.x","article-title":"ET-1 actions in the kidney: evidence for sex differences","volume":"168","author":"Kittikulsuth","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin\u2013angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0330","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0335","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"10.1016\/j.metabol.2016.06.001_bb0340","doi-asserted-by":"crossref","first-page":"F1063","DOI":"10.1152\/ajprenal.90321.2008","article-title":"Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct","volume":"295","author":"Bugaj","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0345","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.2009080885","article-title":"Endothelin-1 inhibits the epithelial Na+ channel through betaPix\/14-3-3\/Nedd 4-2","volume":"21","author":"Pavlov","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lfs.2014.02.025","article-title":"Endothelin receptor antagonists in clinical research--lessons learned from preclinical and clinical kidney studies","volume":"118","author":"Reichetzeder","year":"2014","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.metabol.2016.06.001_bb0355","doi-asserted-by":"crossref","first-page":"R877","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin\u2013angiotensin\u2013aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"8","key":"10.1016\/j.metabol.2016.06.001_bb0360","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0365","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/HYPERTENSIONAHA.111.183368","article-title":"Endothelin 1 activation of endothelin a receptor\/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension","volume":"59","author":"Chen","year":"2012","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.metabol.2016.06.001_bb0370","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.metabol.2015.01.014","article-title":"C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt\/beta-catenin signaling pathway in diabetic kidney disease","volume":"64","author":"Li","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2016.06.001_bb0375","article-title":"New strategies to tackle diabetic kidney disease","author":"Batu","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1016\/j.metabol.2016.06.001_bb0380","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1470320314531058","article-title":"Statins, the renin\u2013angiotensin\u2013aldosterone system and hypertension - a tale of another beneficial effect of statins","volume":"15","author":"Drapala","year":"2014","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"19","key":"10.1016\/j.metabol.2016.06.001_bb0385","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCULATIONAHA.115.016759","article-title":"Statin use and adrenal aldosterone production in hypertensive and diabetic subjects","volume":"132","author":"Baudrand","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0390","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.metabol.2015.10.012","article-title":"Treatment with atorvastatin attenuates progression of insulin resistance and pancreatic fibrosis in the Otsuka Long\u2013Evans Tokushima fatty rats","volume":"65","author":"Wei","year":"2016","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2016.06.001_bb0395","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","article-title":"Plasma aldosterone levels and development of insulin resistance: prospective study in a general population","volume":"58","author":"Kumagai","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.metabol.2016.06.001_bb0400","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","article-title":"Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients","volume":"60","author":"Raheja","year":"2012","journal-title":"Hypertension"}],"updated-by":[{"DOI":"10.1016\/j.metabol.2017.12.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000}}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049516300403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049516300403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:12:09Z","timestamp":1758427929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049516300403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0026049516300403"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2016.06.001","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2016.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}